Plain-English translation of NCT05410717 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of cell therapy called CAR-NK cell therapy, where doctors take your own natural killer immune cells, engineer them in the lab to recognize and attack cancer cells, and then infuse them back into your body. The goal is to see if this treatment is safe and whether it can help shrink advanced cancers that have specific proteins on their surface. Researchers will also test whether adding certain immune-boosting substances or other medications alongside the cells makes the treatment work better.
Advanced solid cancers are often hard to treat with standard therapies alone. This trial exists because scientists believe that engineered immune cells might be a more powerful way to fight these cancers by training your body's own defenses to seek out and destroy tumor cells more effectively.
You likely qualify if…
You likely don't qualify if…
First, doctors will collect some of your blood cells and send them to a lab where they will be engineered and grown over several weeks. Once ready, you will receive an infusion of these cells back into your body, either through a vein or directly into the tumor. You will then have close follow-up appointments to monitor how well the treatment works and watch for any side effects. The exact schedule and duration will depend on which version of the treatment you receive and how your cancer responds.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Enrollment target
~200 participants
Started
June 2022
Primary completion
June 2030
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhenfeng Zhang, MD, PHD
Second Affiliated Hospital of Guangzhou Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.